Astrazeneca Pharma India Limited Receives Import And Market Permission In Form CT-20 For Benralizumab 30Mg/Ml Solution For Injection
December 20, 2020 at 08:44 am EST
AstraZeneca Pharma India Limited has received Import and Market Permission in Form CT-20 (Marketing Authorization) from the Drugs Controller General of India for Benralizumab 30mg/mL solution for injection
(Fasenra). Benralizumab (Fasenra) is indicated as an add-on maintenance treatment for severe asthma with an eosinophilic
phenotype in adult patients. The receipt of this permission paves way for the launch of Benralizumab (Fasenra) in India, subject to the receipt
of related statutory approvals and licenses.